Floatz Rating
BB67/100
Confidence
Indicative
Sponsor
New York State Psychiatric Institute
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
69High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05427981CT.gov Anti-suicidal Effects of Buprenorphine In Depressed Individuals | — | Withdrawn | — | — | — |
NCT03646058CT.gov Add-on Buprenorphine at Analgesic Doses for the Treatment of Severe Suicidal Ideas During a Major Depressive Episode | — | Recruiting | — | — | — |
NCT04276259CT.gov Rapid Antidepressant Improvement Secondary to Excitatory Brain Responses | — | Completed | — | — | — |
NCT04116528CT.gov Opiate Suicide Study in Patients With Major Depression | — | Completed | — | — | — |
NCT02181231CT.gov Buprenorphine Used With Treatment Resistant Depression in Older Adults | — | Completed | — | — | — |
NCT02263248CT.gov Incomplete Response in Late-Life Depression: Getting to Remission With Buprenorphine | — | Completed | — | — | — |
NCT02176291CT.gov Incomplete Response in Late-Life Depression: Getting to Remission With Buprenorphine | — | Completed | — | — | — |
NCT01407575CT.gov Buprenorphine for Treatment Resistant Depression | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Major Depressive Disorder
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Buprenorphine (this asset) | New York State Psychiatric Institute | Approved | BB · 67 |
| Selegiline | Corium Innovations, Inc. | P4 | BBB |
| Risperidone | Johns Hopkins University | P4 | BBB |
| Edivoxetine | Eli Lilly and Company | P3 | BBB |
| (1S,2R)-MILNACIPRAN | Allergan | P4 | BBB |
| Brexpiprazole | Nova Scotia Health Authority | P4 | BBB |
| Vortioxetine | Mayo Clinic | P4 | BBB |
| Amitriptyline | e-Therapeutics PLC | P4 | BBB |
| Desvenlafaxine | Pfizer | P4 | BBB |
+42 more in the Major Depressive Disorder cohort
Other indications for Buprenorphine
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Opiate Dependence | — | P4 | BBB · 76 |
| Osteoarthritis | — | P4 | BBB · 75 |
| Chronic Pain Syndrome | — | P4 | BBB · 73 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Buprenorphine in Major Depressive Disorder. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/buprenorphine-major-depressive-disorder
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →